Related references
Note: Only part of the references are listed.Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma
Maysaa Abdulla et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results
Süleyman Cem Adıyaman et al.
Turkish Journal of Hematology (2019)
Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives
Annalisa Chiappella et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm
Nara Yoon et al.
ONCOTARGET (2017)
Investigation on treatment strategy, prognostic factors, and risk factors for early death in elderly Taiwanese patients with diffuse large B-cell lymphoma
Shih-Feng Cho et al.
SCIENTIFIC REPORTS (2017)
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
A. Kuhnl et al.
ANNALS OF ONCOLOGY (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology
Andrew D. Zelenetz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary
V. A. Morrison et al.
ANNALS OF ONCOLOGY (2015)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
H. Tilly et al.
ANNALS OF ONCOLOGY (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Treatment Patterns and Comparative Effectiveness in Elderly Diffuse Large B-Cell Lymphoma Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis
Paul A. Hamlin et al.
ONCOLOGIST (2014)
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
Richard Delarue et al.
LANCET ONCOLOGY (2013)
Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma
Wolfram Klapper et al.
BLOOD (2012)
Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer
Pierre Soubeyran et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older
Akiko Meguro et al.
LEUKEMIA & LYMPHOMA (2012)
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
Ruth Pettengell et al.
SUPPORTIVE CARE IN CANCER (2012)
Activity and Safety of Dose-Adjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With Poor-Prognostic Untreated Diffuse Large B-Cell Non-Hodgkin Lymphoma
Antonino Musolino et al.
CANCER (2011)
The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age
Sylvain Mareschal et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome
C. Thieblemont et al.
ANNALS OF ONCOLOGY (2008)
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
Heidi Nyman et al.
BLOOD (2007)
Lymphorna incidence patterns by WHO subtype in the United States, 1992-2001
LM Morton et al.
BLOOD (2006)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
